

## Contents

|                             |  |
|-----------------------------|--|
| <b>Foreword</b>             | V  |
| <b>List of Contributors</b> | XV   |
| <br>                        |  |
| <b>1</b>                    | <b>Introduction to Green Chemistry, Organic Synthesis and Pharmaceuticals</b> 1    |
|                             | <i>Roger Sheldon</i>   |
| 1.1                         | The Development of Organic Synthesis 1   |
| 1.2                         | The Environmental Factor 4   |
| 1.3                         | The Role of Catalysis 7  |
| 1.4                         | Green Chemistry: Benign by Design 10   |
| 1.5                         | Ibuprofen Manufacture 11   |
| 1.6                         | The Question of Solvents: Alternative Reaction Media 11                            |
| 1.7                         | Biocatalysis: Green Chemistry Meets White Biotechnology 15                         |
| 1.8                         | Conclusions and Prospects 18   |
|                             | References 18  |
| <br>                        |  |
| <b>2</b>                    | <b>Green Chemistry Metrics</b> 21  |
|                             | <i>Richard K. Henderson, David J.C. Constable, and Concepción Jiménez-González</i> |
| 2.1                         | Introduction 21  |
| 2.2                         | Measuring Resource Usage 24  |
| 2.2.1                       | Focus on Solvents 26   |
| 2.2.2                       | Focus on Renewables 28   |
| 2.2.3                       | Cleaning and Maintenance 30  |
| 2.3                         | Life Cycle Assessment (LCA) 30   |
| 2.4                         | Measuring Chemistry and Process Efficiency 34                                      |
| 2.5                         | Measuring Process Parameters and Emissions 35                                      |
| 2.6                         | Real Time Analysis 36  |
| 2.6.1                       | Scalability 36   |
| 2.6.2                       | Controllability 37   |
| 2.6.3                       | Robustness 38  |

|          |  |           |
|----------|--|-----------|
| 2.7      | Operational Efficiency   | 38        |
| 2.8      | Measuring Energy   | 39        |
| 2.9      | Measuring the Toxicity of All the Substrates   | 40        |
| 2.9.1    | Occupational Exposure Hazard and Risk  | 40        |
| 2.10     | Measuring Degradation Potential  | 43        |
| 2.11     | Measuring the Inherent Safety or Lack of Inherent Safety                                   | 45        |
| 2.12     | Conclusions  | 45        |
|          | References   | 46        |
| <b>3</b> | <b>Solvent Use and Waste Issues</b>  | <b>49</b> |
|          | <i>C. Stewart Slater, Mariano J. Savelski, William A. Carole, and David J.C. Constable</i> |           |
| 3.1      | Introduction to Solvent Use and Waste Issues   | 49        |
| 3.1.1    | Introduction   | 49        |
| 3.1.2    | Process Efficiency Metrics   | 50        |
| 3.1.3    | Impact Beyond the Plant – Solvent Life Cycle   | 51        |
| 3.1.4    | Solvent Utilization  | 52        |
| 3.1.5    | Solvents Used in the Pharmaceutical Industry   | 54        |
| 3.1.6    | Solvent Use in Process Development   | 57        |
| 3.1.7    | Consequences of Excessive Solvent Use  | 59        |
| 3.1.8    | Waste Management Practices in the United States  | 61        |
| 3.2      | Solvent and Process Greenness Scoring and Selection Tools                                  | 64        |
| 3.2.1    | Review of Solvent and Process Scoring Methods  | 64        |
| 3.2.1.1  | Greenness Assessment of Pharmaceutical Processes and Technology                            | 64        |
| 3.2.1.2  | Greenness Scoring Methods for Solvents   | 66        |
| 3.2.1.3  | The GSK Solvent Selection Guide  | 68        |
| 3.2.1.4  | The Rowan Solvent Greenness Index Method   | 70        |
| 3.3      | Waste Minimization and Solvent Recovery  | 73        |
| 3.3.1    | Minimizing Solvent Use   | 73        |
| 3.3.1.1  | Batch versus Continuous Reactors   | 74        |
| 3.3.1.2  | Biosynthetic Processes   | 74        |
| 3.3.1.3  | Solid-State Chemistry  | 75        |
| 3.3.1.4  | Telescoping  | 75        |
| 3.3.2    | Recycling Solvents   | 76        |
| 3.3.2.1  | Methods to Recover and Reuse Solvents  | 76        |
| 3.3.2.2  | Issues with Solvent Recovery and Reuse   | 79        |
|          | Acknowledgments  | 80        |
|          | References   | 81        |
| <b>4</b> | <b>Environmental and Regulatory Aspects</b>  | <b>83</b> |
|          | <i>David Taylor and Vyvyan T. Coombe</i>   |           |
| 4.1      | Historical Perspective   | 83        |
| 4.2      | Pharmaceuticals in the Environment   | 84        |
| 4.2.1    | Presence   | 84        |
| 4.2.2    | Persistence  | 86        |
| 4.2.3    | Bioaccumulation  | 86        |

|          |   |            |
|----------|---|------------|
| 4.2.4    | Ecotoxicology   | 87         |
| 4.2.5    | The Current State of the Science  | 90         |
| 4.3      | Environmental Regulations   | 90         |
| 4.3.1    | Product Regulations   | 91         |
| 4.3.2    | Process Regulations   | 93         |
| 4.3.2.1  | Chemicals Control   | 93         |
| 4.3.2.2  | Integrated Pollution Control  | 95         |
| 4.3.3    | Environmental Quality Regulations   | 97         |
| 4.4      | A Look to the Future  | 98         |
|          | References  | 99         |
| <b>5</b> | <b>Synthesis of Sitagliptin, the Active Ingredient in Januvia® and Janumet®</b>   | <b>101</b> |
|          | <i>Jaume Balsells, Yi Hsiao, Karl B. Hansen, Feng Xu, Norihiro Ikemoto, Andrew Clausen, and Joseph D. Armstrong III</i> |            |
| 5.1      | Introduction  | 101        |
| 5.2      | First-Generation Route  | 102        |
| 5.3      | Sitagliptin through Diastereoselective Hydrogenation of an Enamine. The PGA Enamine-Ester Route                         | 105        |
| 5.4      | The Triazole Fragment   | 109        |
| 5.5      | Direct Preparation of $\beta$ -Keto Amides  | 112        |
| 5.6      | Second-Generation Chiral Auxiliary Route. The PGA Enamine-amide Route   | 115        |
| 5.7      | The Asymmetric Hydrogenation Route  | 116        |
| 5.8      | Purification and Isolation of Sitagliptin (Pharmaceutical Form)   | 122        |
| 5.9      | The Final Manufacturing Route   | 123        |
|          | Acknowledgments   | 125        |
|          | References  | 125        |
| <b>6</b> | <b>The Development of Short, Efficient, Economic, and Sustainable Chemoenzymatic Processes for Statin Side Chains</b>   | <b>127</b> |
|          | <i>Martin Schürmann, Michael Wolberg, Sven Panke, and Hans Kierkels</i>   |            |
| 6.1      | Introduction: Biocatalysis  | 127        |
| 6.2      | The Relevance of Statins  | 128        |
| 6.3      | Biocatalytic Routes to Statin Side Chains   | 129        |
| 6.4      | 2-Deoxy-D-Ribose 5-Phosphate Aldolase (DERA)-Based Routes to Statin Intermediates                                       | 131        |
| 6.4.1    | Chemical Transformations of the DERA Product Toward Statins   | 131        |
| 6.4.2    | Optimization and Scale-Up of the DERA Reaction  | 133        |
| 6.4.2.1  | Deactivation of DERA  | 136        |
| 6.4.2.2  | Enzyme Kinetics   | 136        |
| 6.4.2.3  | Conclusions and Outlook   | 138        |
| 6.4.3    | Improvement of DERA by Directed Evolution   | 139        |
| 6.5      | Conclusions   | 142        |
|          | Acknowledgments   | 143        |
|          | References  | 143        |

|          |  |            |
|----------|--|------------|
| <b>7</b> | <b>The Taxol® Story—Development of a Green Synthesis via Plant Cell Fermentation</b>                     | <b>145</b> |
|          | <i>Pia G. Mountford</i>  |            |
| 7.1      | Introduction   | 145        |
| 7.2      | Discovery and Early Development  | 146        |
| 7.3      | From Extraction of Taxol® from Pacific Yew Tree Bark to Semi-Synthetic Taxol®                            | 147        |
| 7.4      | Taxol® from Plant Cell Fermentation  | 150        |
| 7.5      | Comparison of Semi-Synthetic versus PCF Taxol® Processes: The Environmental Impact                       | 154        |
| 7.5.1    | Semi-Synthetic Process   | 154        |
| 7.5.1.1  | <i>Taxus Baccata</i> Plantations   | 154        |
| 7.5.1.2  | Biomass Waste from Isolating 10-DAB  | 154        |
| 7.5.1.3  | Chemical Synthesis   | 154        |
| 7.5.2    | Plant Cell Fermentation Process  | 155        |
| 7.5.2.1  | Plant Cell Fermentation  | 155        |
| 7.5.2.2  | Crude Paclitaxel Isolation   | 155        |
| 7.5.2.3  | Chromatographic Purification of Crude Paclitaxel   | 155        |
| 7.6      | Comparison of Semi-Synthetic versus PCF Taxol®: Green Chemistry Principles                               | 156        |
| 7.6.1    | Reagent Use  | 156        |
| 7.6.2    | Solvent Use  | 156        |
| 7.6.3    | Energy and Handling Implications   | 157        |
| 7.7      | Final Words  | 158        |
|          | Acknowledgments  | 158        |
|          | References   | 159        |
| <br>     |  |            |
| <b>8</b> | <b>The Development of a Green, Energy Efficient, Chemoenzymatic Manufacturing Process for Pregabalin</b> | <b>161</b> |
|          | <i>Peter J. Dunn, Kevin Hettenbach, Patrick Kelleher, and Carlos A. Martinez</i>                         |            |
| 8.1      | Introduction   | 161        |
| 8.2      | Process Routes to Pregabalin   | 161        |
| 8.2.1    | Classical Resolution Route   | 162        |
| 8.2.2    | Asymmetric Hydrogenation Route to Pregabalin   | 163        |
| 8.2.3    | Non-Pfizer/Parke-Davis Routes to Pregabalin  | 165        |
| 8.3      | Biocatalytic Route to Pregabalin   | 165        |
| 8.3.1    | Enzyme Screening, Optimization, and Recycling of Undesired Enantiomer                                    | 166        |
| 8.3.2    | Subsequent Chemical Steps to Pregabalin  | 170        |
| 8.4      | Green Chemistry Considerations   | 171        |
| 8.4.1    | Material Usage   | 172        |
| 8.4.2    | Energy Usage   | 173        |
| 8.5      | Conclusions  | 176        |
|          | Acknowledgments  | 176        |
|          | References   | 176        |

|           |  |            |
|-----------|--|------------|
| <b>9</b>  | <b>Green Processes for Peptide Mimetic Diabetic Drugs</b>  | <b>179</b> |
|           | <i>Yasuhiro Sawai and Mitsuhsa Yamano</i>  |            |
| 9.1       | Introduction   | 179        |
| 9.2       | Green Chemistry Considerations in Peptide-like API Manufacture                                   | 179        |
| 9.3       | Purification Process to Manufacture Amorphous API  | 182        |
| 9.3.1     | Cation Exchange Chromatography   | 184        |
| 9.3.2     | Extraction   | 186        |
| 9.4       | Preparation of Unnatural Amino Acids   | 187        |
| 9.4.1     | Crystallization-Induced Diastereomer Transformation  | 188        |
| 9.4.2     | Optical Resolution via Diastereomeric Salt Formation   | 191        |
| 9.5       | Summary  | 193        |
|           | Acknowledgments  | 193        |
|           | References   | 193        |
| <br>      |  |            |
| <b>10</b> | <b>The Development of an Environmentally Sustainable Process for Radafaxine</b>                  | <b>197</b> |
|           | <i>Trevor Grinter</i>  |            |
| 10.1      | Introduction   | 197        |
| 10.1.1    | Background   | 198        |
| 10.2      | Chemistry Process and the Dynamic Kinetic Resolution (DKR)                                       | 199        |
| 10.2.1    | General Description of the Chemistry   | 201        |
| 10.2.2    | Route 2  | 202        |
| 10.2.3    | Route 3  | 202        |
| 10.3      | Multicolumn Chromatography–Development of Route 4  | 206        |
| 10.4      | Environmental Assessment   | 212        |
| 10.4.1    | Life Cycle Metrics   | 214        |
| 10.4.2    | Eco-Efficiency Benefits  | 216        |
| 10.5      | Summary  | 217        |
|           | Acknowledgments  | 218        |
|           | References   | 218        |
| <br>      |  |            |
| <b>11</b> | <b>Continuous Processing in the Pharmaceutical Industry</b>                                      | <b>221</b> |
|           | <i>Lee Proctor, Peter J. Dunn, Joel M. Hawkins, Andrew S. Wells, and Michael T. Williams</i>     |            |
| 11.1      | Introduction   | 221        |
| 11.2      | Continuous Production of a Key Intermediate for Atorvastatin                                     | 223        |
| 11.2.1    | Laboratory Screening   | 223        |
| 11.2.2    | Reaction Scale-up  | 225        |
| 11.2.3    | Product Isolation and Waste Treatment  | 226        |
| 11.3      | Continuous Process to Prepare Celecoxib  | 228        |
| 11.4      | Continuous Oxidation of Alcohols to Aldehydes  | 232        |
| 11.5      | Continuous Production of Bromonitromethane   | 234        |
| 11.6      | Continuous Production and Use of Diazomethane  | 235        |
| 11.7      | A Snapshot of Some Further Continuous Processes Used in the Preparation of Pharmaceutical Agents | 238        |

|           |  |            |
|-----------|--|------------|
| 11.8      | Conclusions  | 241        |
|           | Acknowledgments  | 241        |
|           | References   | 241        |
| <b>12</b> | <b>Preparative and Industrial Scale Chromatography: Green and Integrated Processes</b>               | <b>243</b> |
|           | <i>Eric Lang, Eric Valéry, Olivier Ludemann-Hombourger, Wieslaw Majewski, and Jean Bléhaut</i>       |            |
| 12.1      | Introduction   | 243        |
| 12.2      | Basic Principles of Chromatography   | 244        |
| 12.3      | Process Optimization to Reduce Eluent Consumption  | 246        |
| 12.3.1    | Batch Processes  | 247        |
| 12.3.1.1  | Increasing Injected Amount   | 247        |
| 12.3.1.2  | Reducing Cycle Time with Stacked Injections (Case of Isocratic Eluents)                              | 247        |
| 12.3.1.3  | Reducing Cycle Time Using Gradients  | 248        |
| 12.3.2    | Continuous Processes   | 249        |
| 12.4      | Use of a Green Solvent: Supercritical Carbon Dioxide   | 252        |
| 12.5      | Solvent Recycling Technologies   | 255        |
| 12.5.1    | Recycling Devices for Isocratic Chromatography   | 256        |
| 12.5.2    | Recycling Devices for Gradient Chromatography  | 257        |
| 12.5.3    | Recycling Devices for Supercritical Carbon Dioxide   | 258        |
| 12.6      | Application Examples   | 259        |
| 12.6.1    | Optimization of a Batch Process  | 259        |
| 12.6.2    | Selection of the Chromatographic Conditions  | 259        |
| 12.6.3    | Scale-up on a Pilot SFC Unit   | 261        |
| 12.6.4    | Optimization of an MCC Process   | 264        |
| 12.7      | Conclusion: An Environmentally Friendly Solution for Each Separation                                 | 264        |
|           | Acknowledgment   | 266        |
|           | References   | 266        |
| <b>13</b> | <b>Dynamic Resolution of Chiral Amine Pharmaceuticals: Turning Waste Isomers into Useful Product</b> | <b>269</b> |
|           | <i>John Blacker and Catherine E. Headley</i>   |            |
| 13.1      | Background   | 269        |
| 13.1.1    | Chiral Amine Resolution Processes  | 269        |
| 13.1.2    | Homochiral Amine Racemization Processes  | 272        |
| 13.2      | Integration of Chiral Amine Resolution and Racemization  | 276        |
| 13.2.1    | Dynamic Resolution Processes   | 276        |
| 13.3      | Case Studies   | 279        |
| 13.3.1    | Asymmetric Transformation of (S)-7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-amine                      | 279        |
| 13.3.2    | Asymmetric Transformation of (R)-1-tert-butyloxycarbonyl-3-aminopyrrolidine                          | 281        |

|           |  |            |
|-----------|--|------------|
| 13.3.3    | Sertraline   | 282        |
| 13.4      | Conclusions  | 286        |
|           | Acknowledgments  | 287        |
|           | References   | 287        |
| <b>14</b> | <b>Green Technologies in the Generic Pharmaceutical Industry</b> | <b>289</b> |
|           | <i>Apurba Bhattacharya and Rakeshwar Bandichhor</i>              |            |
| 14.1      | Introduction   | 289        |
| 14.2      | 'Waste': Definition and Remedy                                   | 292        |
| 14.3      | Amidation  | 293        |
| 14.3.1    | Carbodiimide and Acid Chloride Mediated Transformation           | 293        |
| 14.3.2    | Metal-Catalyzed Oxidative Amide Synthesis                        | 294        |
| 14.3.2.1  | Copper-Catalyzed Amide Synthesis                                 | 294        |
| 14.3.2.2  | Palladium-Catalyzed Amide Synthesis                              | 294        |
| 14.3.2.3  | Ruthenium-Catalyzed Amide Synthesis                              | 295        |
| 14.3.3    | N-Heterocyclic Carbene (NHC-Catalyzed Amidation)                 | 296        |
| 14.3.4    | Amidation Catalyzed by Boric Acid Derivatives                    | 297        |
| 14.4      | Synthesis of Galanthamine  | 298        |
| 14.5      | Synthesis of Solefinacin   | 298        |
| 14.5.1    | Precedented Approach   | 298        |
| 14.5.2    | A Greener Approach   | 299        |
| 14.6      | Synthesis of Levetiracetam                                       | 300        |
| 14.6.1    | Established Approach   | 300        |
| 14.6.2    | A More Eco-Friendly Synthesis                                    | 301        |
| 14.7      | Synthesis of a Finasteride Intermediate                          | 301        |
| 14.7.1    | The Classical Approach   | 301        |
| 14.7.2    | Problems with the Existing Synthesis                             | 302        |
| 14.7.3    | A Catalytic Approach   | 302        |
| 14.8      | Bromination  | 304        |
| 14.8.1    | Current Zafirlukast Bromination Method                           | 304        |
| 14.8.2    | Environmental Burden   | 305        |
| 14.8.3    | Waste-Minimized Bromination                                      | 305        |
| 14.9      | Sulfoxidation in the Synthesis of Rabeprazole                    | 306        |
| 14.9.1    | The Traditional Approach   | 306        |
| 14.9.2    | A Greener Approach   | 307        |
| 14.10     | Conclusions  | 307        |
|           | Acknowledgments  | 308        |
|           | References   | 308        |
| <b>15</b> | <b>Environmental Considerations in Biologics Manufacture</b>     | <b>311</b> |
|           | <i>Sa V. Ho</i>  |            |
| 15.1      | Introduction   | 311        |
| 15.2      | Therapeutic Biologics  | 312        |
| 15.2.1    | Types of Therapeutic Biologics                                   | 312        |
| 15.2.2    | General Features of Therapeutic Protein Manufacture              | 314        |

|           |  |            |
|-----------|--|------------|
| 15.3      | Environmental Impact Considerations  | 317        |
| 15.3.1    | Microbially Produced Proteins  | 317        |
| 15.3.1.1  | Insulin Production Process   | 317        |
| 15.3.1.2  | Production of a Typical Medium-Sized Protein                                       | 318        |
| 15.3.1.3  | Highly Efficient Protein Manufacturing Process                                     | 319        |
| 15.3.2    | Monoclonal Antibodies and Mammalian Cell Culture Processes                         | 321        |
| 15.3.2.1  | Typical-to-Optimized Manufacturing Process for mAbs                                | 322        |
| 15.3.2.2  | Projected 'Intensified' Large-Scale Monoclonal Antibody Manufacturing Process      | 322        |
| 15.4      | Overall Comparison   | 324        |
| 15.5      | Environmental Indices for Therapeutic Protein Manufacture                          | 325        |
| 15.6      | Technologies with Potential Environmental Impact                                   | 327        |
| 15.7      | Single-Use Biologics Manufacture   | 328        |
| 15.8      | Summary  | 329        |
|           | Acknowledgments  | 330        |
|           | References   | 330        |
| <b>16</b> | <b>Future Trends for Green Chemistry in the Pharmaceutical Industry</b>            | <b>333</b> |
|           | <i>Peter J. Dunn, Andrew S. Wells, and Michael T. Williams</i>                     |            |
| 16.1      | Introduction   | 333        |
| 16.2      | Waste Minimization in Drug Discovery   | 334        |
| 16.3      | Greener Synthetic Methods in Primary Manufacturing                                 | 338        |
| 16.3.1    | Synthesis Design and Execution   | 338        |
| 16.3.2    | Reduction and Oxidation  | 339        |
| 16.3.3    | C–C Bond Formation   | 340        |
| 16.3.4    | Heteroatom Alkylation and Acylation  | 341        |
| 16.3.5    | Biocatalysis Now and Into the Future   | 341        |
| 16.3.6    | Application of Technology  | 343        |
| 16.4      | Alternative Solvents in the Pharmaceutical Industry                                | 344        |
| 16.4.1    | Water  | 345        |
| 16.4.2    | Ionic Liquids (ILs)  | 345        |
| 16.4.3    | Fluorous Solvents  | 346        |
| 16.4.4    | Supercritical CO <sub>2</sub> (SC-CO <sub>2</sub> ) and Gas-Expanded Liquids (GXL) | 346        |
| 16.4.5    | Molecular Solvents from Renewable Sources  | 347        |
| 16.4.6    | Solid-Phase Reactions  | 348        |
| 16.4.7    | The Work-Up  | 348        |
| 16.4.8    | Obstacles to Change  | 349        |
| 16.5      | Green Chemistry in Secondary Pharmaceutical Operations                             | 349        |
| 16.6      | Global Cooperation in Green Chemistry  | 351        |
| 16.6.1    | The Pharmaceutical Roundtable  | 351        |
| 16.6.2    | Recognition  | 352        |
| 16.6.3    | The Global Impact  | 352        |
| 16.7      | Conclusions  | 353        |
|           | References   | 353        |
|           | <b>Index</b>   | <b>357</b> |